The glycation pathway in type 2 diabetes and cardiovascular disease

L. Engelen

Research output: ThesisDoctoral ThesisInternal

773 Downloads (Pure)


The increased formation of glycated proteins (advanced glycation end products (AGE’s)) is a possible mechanism to explain the increased risk of cardiovascular diseases with diabetes. Although earlier (animal) experimental studies have shown this role of AGE’s, research for this dissertation does not establish a connection between AGE’s in the blood and cardiovascular diseases in persons with diabetes type 2. Moreover, there is no definite epidemiologic proof for favourable effects of specific AGE-inhibiting treatments and for decreasing AGE’s in blood by existing treatments. This does not mean that AGE’s are unimportant in the development of diabetes 2 related cardiovascular diseases, but it does mean that the current biomarkers in blood don’t sufficiently reflect damage in tissues as a result of AGE’s. Better biomarkers are therefore needed.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Maastricht University
  • Stehouwer, Coen, Supervisor
  • Schalkwijk, Casper, Supervisor
  • Ferreira de Sousa, Maria, Co-Supervisor
Award date12 Oct 2012
Place of PublicationMaastricht
Print ISBNs978 94 6191 421 7
Publication statusPublished - 1 Jan 2012


  • cardiovascular diseases
  • diabetes type 2
  • glycated proteins
  • biomarkers

Cite this